...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>clinical drug investigation >Efficacy and Safety of Quinfamide versus Secnidazole in the Management of Amoebic Non-Dysenteric Colitis in Children
【24h】

Efficacy and Safety of Quinfamide versus Secnidazole in the Management of Amoebic Non-Dysenteric Colitis in Children

机译：Efficacy and Safety of Quinfamide versus Secnidazole in the Management of Amoebic Non-Dysenteric Colitis in Children

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相关主题

摘要

ObjectiveTo compare the efficacy and safety of single doses of quinfamide and secnidazole in the treatment of amoebic non-dysenteric colitis in children.DesignThis was a prospective, longitudinal, double-blind, randomised, comparative study.SettingThe participants were students or relatives of students at two urban elementary schools in Celaya, Guanajuato, Mexico.ParticipantsPatients aged between 2 and 15 years of age with cysts ofEntamoeba histolyticain stool samples for 3 consecutive days as detected by Faustrsquo;s concentration method were enrolled in this study.Interventions and Outcome MeasuresSingle doses of quinfamide 4.3 mg/kg or secnidazole 30 mg/kg were administered. Patients were asked about the acceptability of the flavour of the drugs. Efficacy was evaluated by the presence or absence ofE.histolyticacysts in stool samples on the fifth, sixth and seventh days after administration of the drugs. Adverse events were evaluated by direct questioning of patients.Results734 patients were evaluated by coproparasitoscopy, of whom 239 (32.6) hadE.histolyticacysts. 112 patients were randomised to receive quinfamide and 127 to receive secnidazole. Differences in age, bodyweight, size and gender distribution were not statistically significant between the groups. 108 patients (96) in the quinfamide group and 15 patients (12) in the secnidazole group reported the flavour as good (p 0.0001). 95 patients (85) in the quinfamide group and 93 patients (73) in the secnidazole group had negative stool samples at the end of treatment (p = 0.04). Nausea (p 0.0001), abdominal pain (p 0.05) and unpleasant taste (i.e. metallic taste 3 to 5 days after administration of secnidazole) in mouth (p 0.0001) were more common in the secnidazole group than in the quinfamide group.ConclusionsQuinfamide is an excellent option for amoebic non-dysenteric colitis because of its high parasitoscopic efficacy, minimum adverse effects and good acceptance by children. The single-dose schedule guarantees completion of treatment.

著录项

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号